established three groups of models (spontaneous T1D model disease delay study, cyclophosphamide (CP) accelerated T1D model disease delay study and α PD-1 accelerates T1D mode disease delay research) and showed that PD-1+ not only helped to control autoimmune diseases, but also maintained the normal adaptive immunity of the body (31, 83, 84).Therefore, we speculated that PD-1 agonists might be able to achieve specific inhibition of highly activated immune cells through PD-1 inhibition signals. Here, PDCD1 is linked to type 1 diabetes mellitus.